Find and Pitch Jounalists, Get Your Story Covered

Tags: Celltrion subcutaneous infliximab inflammatory bowel disease infliximab infection

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Inebilizumab for Myasthenia Gravis Reduces Steroid Burden - 11 days ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 11 months ago New Guselkumab Responses in Ulcerative Colitis Emerge After 12 Weeks - about 1 year ago New Data on CD40 Ligand Inhibitor for Relapsing MS - about 1 year ago
2	Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA Healthcareoncologypharmacyeducation	SC vs IV Administration Methods - 17 days ago
3	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 20 days ago Investigational Once-Monthly Injectable Boosts Response Rate in Acromegaly - 4 months ago
4	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Sustained Disease Control in Adolescent Myasthenia Gravis With FcRn Blocker - 29 days ago Subcutaneous Alzheimer's Drug May Be on the Horizon - about 1 year ago
5	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Celltrion unveils promising dose escalation results for subcutaneous infliximab - about 1 month ago Amgen’s trial brings new hope for IgG4-RD patients - 5 months ago
6	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs - 2 months ago
7	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - 9 months ago New First-Line Option for Pancreatic Cancer Approved - 9 months ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - 11 months ago Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago
8	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 2 months ago FDA Approves Axatilimab-csfr for cGVHD - 3 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 8 months ago
9	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Lebrikizumab Wins FDA Approval for Eczema - 2 months ago FDA Expands Durvalumab Label to Operable Lung Cancer - 3 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 11 months ago
10	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - 2 months ago

Journalists covering subcutaneous infliximab